Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
new york top stories
pfizer
10
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
10
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
bristol-myers squibb
abbvie
alzheimer's disease
cancer
clinical trials
deals
medicare
merck
novartis
president trump
startups
astrazeneca
What
drug
10
×
bio
roundup
week
alzheimer’s
approved
news
prices
acquisitions
biggest
biogen
ceo
companies
fda
nash
patients
pharmaceutical
plan
today
adu
aducanumab
advantages
afternoon
albert
alnylam
alnylam’s
amyloid
angst
annual
assessed
attention
away
bagged
bar
beats
bids
billions
biogen’s
biotech
bourla
Language
unset
unknown
Current search:
drug
×
" san francisco top stories "
×
pfizer
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug